Fulcrum Therapeutics, Inc.
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

Last updated:

Abstract:

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: ##STR00001## or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X.sub.1, X.sub.2, X.sub.3, A.sub.1, A.sub.2, Y, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are as described herein.

Status:
Grant
Type:

Utility

Filling date:

24 Apr 2020

Issue date:

13 Apr 2021